174 related articles for article (PubMed ID: 36195679)
1. Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil.
Sakatoku K; Kim SW; Okamura H; Kanaya M; Kato K; Yamasaki S; Uchida N; Kobayashi H; Fukuda T; Takayama N; Ishikawa J; Nakazawa H; Sakurai M; Ikeda T; Kondo T; Yoshioka S; Miyamoto T; Kimura T; Ichinohe T; Atsuta Y; Kondo E
Ann Hematol; 2022 Dec; 101(12):2743-2757. PubMed ID: 36195679
[TBL] [Abstract][Full Text] [Related]
2. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
[TBL] [Abstract][Full Text] [Related]
3. Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI.
Yamada Y; Ikegawa S; Najima Y; Atsuta Y; Konuma R; Adachi H; Wada A; Kishida Y; Konishi T; Nagata A; Kaito S; Nagata R; Noguchi Y; Marumo A; Mukae J; Inamoto K; Toya T; Igarashi A; Kobayashi T; Sakamaki H; Ohashi K; Doki N
Int J Hematol; 2022 Feb; 115(2):244-254. PubMed ID: 34652634
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.
Bejanyan N; Rogosheske J; DeFor TE; Lazaryan A; Arora M; Holtan SG; Jacobson PA; MacMillan ML; Verneris MR; Blazar BR; Weisdorf DJ; Wagner JE; Brunstein CG
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2025-2030. PubMed ID: 27519278
[TBL] [Abstract][Full Text] [Related]
5. High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
Radujkovic A; Hegenbart U; Müller-Tidow C; Herfarth K; Dreger P; Luft T
Ann Hematol; 2020 Apr; 99(4):855-866. PubMed ID: 32036420
[TBL] [Abstract][Full Text] [Related]
6. Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation.
Harada K; Fuji S; Seo S; Uchida N; Kawakita T; Yano S; Ozawa Y; Yoshioka S; Onishi Y; Noguchi Y; Onizuka M; Matsuhashi Y; Kimura T; Ichinohe T; Atsuta Y; ; ; Terakura S; Nakasone H
Bone Marrow Transplant; 2021 Feb; 56(2):400-410. PubMed ID: 32820226
[TBL] [Abstract][Full Text] [Related]
7. Cord blood transplantation from unrelated donors for children with acute lymphoblastic leukemia in Japan: the impact of methotrexate on clinical outcomes.
Kato K; Yoshimi A; Ito E; Oki K; Hara J; Nagatoshi Y; Kikuchi A; Kobayashi R; Nagamura-Inoue T; Kai S; Azuma H; Takanashi M; Isoyama K; Kato S;
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1814-21. PubMed ID: 21664471
[TBL] [Abstract][Full Text] [Related]
8. Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation.
Yoshida S; Ohno Y; Nagafuji K; Yoshimoto G; Sugio T; Kamimura T; Ohta T; Takase K; Henzan H; Muta T; Iwasaki H; Ogawa R; Eto T; Akashi K; Miyamoto T
Ann Hematol; 2019 Nov; 98(11):2579-2591. PubMed ID: 31628517
[TBL] [Abstract][Full Text] [Related]
9. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
Piñana JL; Valcárcel D; Martino R; Barba P; Moreno E; Sureda A; Vega M; Delgado J; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Jan; 15(1):21-9. PubMed ID: 19135939
[TBL] [Abstract][Full Text] [Related]
10. Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch.
Yokoyama H; Kanaya M; Iemura T; Hirayama M; Yamasaki S; Kondo T; Uchida N; Takahashi S; Tanaka M; Onizuka M; Ozawa Y; Kozai Y; Eto T; Sugio Y; Hamamura A; Kawakita T; Aotsuka N; Takada S; Wake A; Kimura T; Ichinohe T; Atsuta Y; Yanada M; Morishima S
Bone Marrow Transplant; 2022 Jul; 57(7):1171-1179. PubMed ID: 35538140
[TBL] [Abstract][Full Text] [Related]
11. Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
Abraham A; Cluster A; Jacobsohn D; Delgado D; Hulbert ML; Kukadiya D; Murray L; Shenoy S
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1587-1592. PubMed ID: 28578010
[TBL] [Abstract][Full Text] [Related]
12. Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.
Terakura S; Kuwatsuka Y; Sugita J; Takahashi S; Ozawa Y; Ozeki K; Yoshioka S; Nakamae H; Kawakita T; Sawa M; Morishige S; Najima Y; Katsuoka Y; Sakaida E; Kouzai Y; Kimura T; Ichinohe T; Fukuda T; Atsuta Y; Murata M; Teshima T
Int J Hematol; 2021 Jun; 113(6):840-850. PubMed ID: 33611725
[TBL] [Abstract][Full Text] [Related]
13. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
14. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil.
Terakura S; Wake A; Inamoto Y; Murata M; Sakai R; Yamaguchi T; Takahashi S; Uchida N; Onishi Y; Ohashi K; Ozawa Y; Kanamori H; Yamaguchi H; Fukuda T; Ichinohe T; Takanashi M; Atsuta Y; Teshima T
Bone Marrow Transplant; 2017 Mar; 52(3):423-430. PubMed ID: 27941766
[TBL] [Abstract][Full Text] [Related]
15. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
[TBL] [Abstract][Full Text] [Related]
17. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
Piñana JL; Valcárcel D; Fernández-Avilés F; Martino R; Rovira M; Barba P; Martínez C; Brunet S; Sureda A; Carreras E; Sierra J
Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024
[TBL] [Abstract][Full Text] [Related]
18. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
Kennedy VE; Savani BN; Greer JP; Kassim AA; Engelhardt BG; Goodman SA; Sengsayadeth S; Chinratanalab W; Jagasia M
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1801-1807. PubMed ID: 27377900
[TBL] [Abstract][Full Text] [Related]
19. Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies.
Imahashi N; Terakura S; Kondo E; Kako S; Uchida N; Kobayashi H; Inamoto Y; Sakai H; Tanaka M; Ishikawa J; Kozai Y; Matsuoka KI; Kimura T; Fukuda T; Atsuta Y; Kanda J;
Bone Marrow Transplant; 2020 Nov; 55(11):2098-2108. PubMed ID: 32440015
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]